Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T

Purpose: We examined the efficacy of Suplatast Tosilate double dagger (IPD- 1151T), a new immunoregulator that suppresses helper T cell mediated allerg ic responses, including IgE production and eosinophilic inflammation for tr eating patients with interstitial cystitis. Materials and Methods: A total of 14 women (average age 43.7 years) with in terstitial cystitis, which was nonulcerative in 13 and ulcerative in 1, wer e treated with 300 mg. IPD-1151T orally daily for 12 months. All patients r eceived laboratory assessments, including hematology (eosinophils and CD20 positive cells) and serum chemistry (IgE, and interleukin-4 (IL-4) and 5 an d immunohistochemical analyses of urine leukocytes (CD45RO positive cells a s a T cell marker) before treatment. These parameters were also measured 4 and 12 months after continuous treatment. The voiding chart, and interstiti al cystitis symptom and problem indexes were evaluated before and after IPD -1151T treatment. Results: IPD-1151T treatment for 1 year resulted in a significantly increas ed bladder capacity and decreased symptoms, such as urinary urgency, freque ncy and lower abdominal pain, in patients with nonulcerative interstitial c ystitis. These effects also correlated with a reduction in blood eosinophil s, CD20 positive cells and IgE, and urine CD45RO positive memory T cells. N o major side effects were observed. Conclusions: Our study suggests that immunological responses are involved i n the development of interstitial cystitis symptoms. IPD-1151T could be a n ew oral agent for treatment of voiding symptoms and bladder pain in patient s with interstitial cystitis.